Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Kidney deficiency" is not a scientific or canonical molecular target. The term is used colloquially, especially in non-technical contexts, to denote reduced kidney function. In medical science, the appropriate terms are "chronic kidney disease" (CKD) or "renal insufficiency," which refer to a progressive loss of kidney function. Neither "kidney deficiency" nor its variants represent a single molecule, receptor, enzyme, or other druggable target, but rather a disease state resulting from damage to multiple renal components, including nephrons, glomeruli, or renal vasculature. Treatment of CKD addresses underlying causes (such as diabetes or hypertension), symptomatic management, and renal replacement therapy at end-stage. In summary, "kidney deficiency" is not a molecular entity or valid drug target. It is a descriptive term for kidney dysfunction. The canonical terms for the pathophysiological state described are "chronic kidney disease" or "renal insufficiency."
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kidney deficiency.